- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 1,207
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myelodysplastic Syndrome, Anemia
- Interventions
- Elritercept, Epoetin Alfa
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Duarte, California • Santa Rosa, California + 30 more
- Conditions
- Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases
- Interventions
- TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet
- Drug
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pemziviptadil (PB1046)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
- Conditions
- Autism, Attention Deficit Disorder With Hyperactivity
- Interventions
- Methylphenidate-extended release, Methylphenidate-immediate release, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 7 Years to 12 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Opioid Use Disorder
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Melanoma, Cutaneous Malignant, Mucosal Melanoma
- Interventions
- IMA203, nivolumab plus relatlimab, lifileucel, nivolumab, pembrolizumab, ipilimumab, Dacarbazine, temozolomide, paclitaxel, paclitaxel plus carboplatin, Albumin-Bound Paclitaxel
- Biological · Drug
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
- Conditions
- Covid19
- Interventions
- theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
- Drug
- Lead sponsor
- Matthew Neal MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Cancer, Cancers, Pain
- Interventions
- Oral cannabis low THC, Placebo Comparator, Oral cannabis high THC, Oral cannabis THC/CBD
- Drug
- Lead sponsor
- Shanna Babalonis, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Adverse Pregnancy Outcome
- Interventions
- Lovenox 40mg
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Infertility, Female
- Interventions
- Lovenox, Aspirin, Embryo transfer
- Drug · Procedure
- Lead sponsor
- Fertility Center of Las Vegas
- Industry
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Alzheimer's Disease
- Interventions
- Posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Golvatinib, Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Fenofibric Acid 105 mg Tablet
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Dengue
- Interventions
- Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Scar Prevention, Scar Reduction
- Interventions
- AZX100 Drug Product, Placebo
- Drug
- Lead sponsor
- Capstone Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Austin, Texas
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression
- Interventions
- electroconvulsive therapy (ECT), Ketamine
- Procedure · Drug
- Lead sponsor
- Bo Hu
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • New York, New York + 2 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
- Procedure · Radiation · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Statin Adverse Reaction
- Interventions
- Low-dose colchicine at 0.5mg daily, Placebo
- Drug · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Respiratory Distress Syndrome in Premature Infant
- Interventions
- AeroFact, nCPAP
- Drug · Other
- Lead sponsor
- Aerogen Pharma Limited
- Industry
- Eligibility
- 26 Weeks to 31 Weeks
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more
- Conditions
- Advanced Metastatic Cancer, Advanced Prostate Cancer
- Interventions
- Nivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer, Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer
- Biological
- Lead sponsor
- Parker Institute for Cancer Immunotherapy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 3 more
- Conditions
- Acute Mountain Sickness
- Interventions
- Prochlorperazine Maleate, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Evergreen, Colorado
- Conditions
- Venous Thromboembolism
- Interventions
- TAK-442, Enoxaparin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,045 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more